Many people with developmental disability are sedentary and obese, have poor diet, and consequently suffer from conditions such as cardiovascular disease, osteoporosis, hypertension and type 2 diabetes. Promoting healthy lifestyles for this group is the aim of a new project that teams University of Illinois at Chicago researchers with two community-based nonprofit organizations in Albuquerque, N ...
On average, a lower blood pressure goal was no better than the standard blood pressure goal at slowing progression of kidney disease among African-Americans who had chronic kidney disease resulting from high blood pressure, according to results of the African-American Study of Kidney Disease and Hypertension (AASK), the largest and longest study of chronic kidney disease (CKD) in African ...
Intensively treating hypertension in some African Americans with kidney disease by pushing blood pressure well below the current recommended goal may significantly decrease the number who lose kidney function and require dialysis, suggests a Johns Hopkins-led study publishing in the New England Journal of Medicine Thursday. "This is not a panacea. We have a lot more to figure out. But our ...
Allergan, Inc. (NYSE:AGN) announced the United States Food and Drug Administration (FDA) has approved LUMIGANĀ® (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGANĀ® 0.01% is an optimized reformulation of LUMIGANĀ® (bimatoprost ophthalmic solution) 0.03 ...
Data show that treatment with a single-pill combination of telmisartan, an angiotensin receptor blocker, (ARB) and amlodipine, a calcium channel blocker (CCB) results in significant reductions in blood pressure (BP) in patients with severe hypertension.